Comparison of the effects of three agents used in the treatment of disease of the pulp in permanent posterior teeth in the Nigerian adult population - Trial PACTR202308547851267
Access comprehensive clinical trial information for PACTR202308547851267 through Pure Global AI's free database. This Phase 3 trial is sponsored by Igweagu Chibuzor Emmanuel and is currently Completed. The study focuses on Oral Health.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
drug
Sponsor & Location
Igweagu Chibuzor Emmanuel
Timeline & Enrollment
Phase 3
Jul 14, 2021
Dec 19, 2022
Summary
Reversible pulpitis from deep carious lesion is a common disease entity in Dentistry worldwide. Indirect pulp capping is the recommended treatment. Calcium hydroxide has been the most common agent used in our environment. Newer agents are being developed and domesticated in other countries. It will be worthwhile to evaluate the newer agents against the commonly used in our environment. The study's objectives include1. To compare the clinical outcomes after treatment with calcium hydroxide, Mineral trioxide aggregate and Biodentine2. To compare the radiological outcomes following successful clinical outcomes with the same agents3. To compare the effects of age , gender and site of carious lesion on clinical outcomes
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR202308547851267
Non-Device Trial